An updated guide to treating stroke

N. Schellack; N. Smith; L. van Tonder; E. J. Fourie

An updated guide to treating stroke

N. Schellack^*, N. Smith, L. van Tonder, E. J. Fourie

^*Corresponding author for this work

Clinical Pharmacy

Research output: Contribution to journal › Review article › peer-review

Abstract

Stroke is one of the leading causes of mortality worldwide. Stroke can either be haemorrhagic (13%) or ischaemic (87%) in nature. Within the first few days of stroke, transient ischaemic attacks may occur and will require urgent intervention. However, this is often missed by healthcare workers. This article outlines the current evidence-based practice for stroke management and care. Based on the aetiology, this may include early reperfusion with a tissue plasminogen activator (t-PA), antiplatelet therapy and warfarin. This paper outlines many of the recommendations of the published National Clinical Guidelines for Stroke. It also covers aspects of multidisciplinary stroke care, from initial assessment and acute treatment, to rehabilitation strategies and the management of complications.

Original language	English
Pages (from-to)	26-34
Number of pages	9
Journal	SA Pharmaceutical Journal
Volume	87
Issue number	4
Publication status	Published - 1 Jan 2020

Keywords

Haemorrhagic stroke
Hypertension
Ischaemic stroke
Reperfusion
Stroke
Tissue plasminogen activator

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{801a06c3d2864f1b9409c1c3bbedcf07,

title = "An updated guide to treating stroke",

abstract = "Stroke is one of the leading causes of mortality worldwide. Stroke can either be haemorrhagic (13%) or ischaemic (87%) in nature. Within the first few days of stroke, transient ischaemic attacks may occur and will require urgent intervention. However, this is often missed by healthcare workers. This article outlines the current evidence-based practice for stroke management and care. Based on the aetiology, this may include early reperfusion with a tissue plasminogen activator (t-PA), antiplatelet therapy and warfarin. This paper outlines many of the recommendations of the published National Clinical Guidelines for Stroke. It also covers aspects of multidisciplinary stroke care, from initial assessment and acute treatment, to rehabilitation strategies and the management of complications.",

keywords = "Haemorrhagic stroke, Hypertension, Ischaemic stroke, Reperfusion, Stroke, Tissue plasminogen activator",

author = "N. Schellack and N. Smith and {van Tonder}, L. and Fourie, {E. J.}",

note = "Publisher Copyright: {\textcopyright} Medpharm",

year = "2020",

month = jan,

day = "1",

language = "English",

volume = "87",

pages = "26--34",

journal = "SA Pharmaceutical Journal",

issn = "2221-5875",

publisher = "Medpharm Publications",

number = "4",

}

TY - JOUR

T1 - An updated guide to treating stroke

AU - Schellack, N.

AU - Smith, N.

AU - van Tonder, L.

AU - Fourie, E. J.

N1 - Publisher Copyright: © Medpharm

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Stroke is one of the leading causes of mortality worldwide. Stroke can either be haemorrhagic (13%) or ischaemic (87%) in nature. Within the first few days of stroke, transient ischaemic attacks may occur and will require urgent intervention. However, this is often missed by healthcare workers. This article outlines the current evidence-based practice for stroke management and care. Based on the aetiology, this may include early reperfusion with a tissue plasminogen activator (t-PA), antiplatelet therapy and warfarin. This paper outlines many of the recommendations of the published National Clinical Guidelines for Stroke. It also covers aspects of multidisciplinary stroke care, from initial assessment and acute treatment, to rehabilitation strategies and the management of complications.

AB - Stroke is one of the leading causes of mortality worldwide. Stroke can either be haemorrhagic (13%) or ischaemic (87%) in nature. Within the first few days of stroke, transient ischaemic attacks may occur and will require urgent intervention. However, this is often missed by healthcare workers. This article outlines the current evidence-based practice for stroke management and care. Based on the aetiology, this may include early reperfusion with a tissue plasminogen activator (t-PA), antiplatelet therapy and warfarin. This paper outlines many of the recommendations of the published National Clinical Guidelines for Stroke. It also covers aspects of multidisciplinary stroke care, from initial assessment and acute treatment, to rehabilitation strategies and the management of complications.

KW - Haemorrhagic stroke

KW - Hypertension

KW - Ischaemic stroke

KW - Reperfusion

KW - Stroke

KW - Tissue plasminogen activator

UR - http://www.scopus.com/inward/record.url?scp=85105956005&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:85105956005

SN - 2221-5875

VL - 87

SP - 26

EP - 34

JO - SA Pharmaceutical Journal

JF - SA Pharmaceutical Journal

IS - 4

ER -

An updated guide to treating stroke

Abstract

Keywords

UN SDGs

Other files and links

Fingerprint

Cite this